The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) Class III and IV, to patients suffering from PAH Class II.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
185
exercise capacity
Time frame: Baseline to end of study
cardiac hemodynamics
Time frame: Baseline to end of study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
University of Alabama-Birmingham
Birmingham, Alabama, United States
Harbor UCLA Medical Center
Torrance, California, United States
Tufts- New England Medical Center
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
St. Paul University Hospital
Dallas, Texas, United States
The Prince Charles Hospital
Brisbane, Australia
Royal Prince Albert Hospital
Camperdown, Australia
St. Vincent's Hospital
Darlinghurst, Australia
General Hospital of Vienna
Vienna, Austria
...and 24 more locations